A classic example of this highly relevant clinical phenomenon is provided by the initial, and subsequent, phase 3 randomized trials employing the then novel regimen of cisplatin plus paclitaxel in the treatment of advanced stage epithelial ovarian cancer [3, 4] . In the first trial, conducted by the Gynecologic Oncology Group (USA), the median progression-free and overall survivals of this relatively large population treated with cisplatin plus paclitaxel were 18 and 38 months, respectively [3] . However, when the exact treatment regimen ( drugs, doses, schedules) was employed by the same group of oncologists in their next trial, the identical patient population (tumor stage, grade, age, etc.) was found to experience a rather striking reduction in clinical outcome (median progression-free and overall survivals, 14 and 27 months,
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While it is not possible to know precisely why the treated 'populations' (as opposed to any individual ovarian cancer patient managed with cisplatin plus paclitaxel) experienced such different outcomes, one can speculate that increasing physician comfort with the potential toxicities of this drug combination (based on the results of the initial landmark study [3] ) led to subsequent study entry of individuals with greater co-morbidity (including histories of pre-existing cardiac dysfunction) and a more It is appropriately appreciated that there are inherent dangers associated with any attempt to directly compare the outcomes observed in independently conducted clinical trials. This is particularly problematic in the oncology arena where it is recognized there is frequently tremendous heterogeneity within patient populations as regards well-defined and currently poorly understood disease characteristics [1] . Further, populations differ in pre-existing co-morbidity, and outcomes may be substantially influenced by provider/institutional skills (particularly in the realm of surgery or technically demanding procedure-oriented medical care) [2] .
In the absence of randomization within a single trial, where specific efforts are unable to be employed to 'control' for such variations (e.g. tumor grade, age, performance status, etc.) it is far more than a theoretical possibility that any observed differences in outcomes associated with employing different research strategies in 'identical' patient populations (tumor type and stage) will actually be due to relevant (but possibly not appreciated) differences in the specific patient populations who were entered into the individual studies, rather than to the superiority (or conversely, inferiority) of one management approach compared to an alternative. compromised performance status [4] . It is important to note that there was absolutely nothing wrong with the individual randomized studies, but the outcomes strongly suggest there were major differences in the patient populations who actually entered the two trials.
Therefore, is it appropriate to inquire if it is ever permissible to cross-compare the outcomes of individual non-randomized clinical studies in the belief it will be possible to document that observed differences between the studies are of legitimate clinical relevance?
In the opinion of this commentator the answer is yes , particularly in settings where great care is taken to observe for potential differences in known relevant clinical features of the populations (e.g. age, tumor grade, performance status, co-morbidity, etc.) and where the specific focus of the intended comparison is on insuring patient safety , rather than any claim of 'improved efficacy'.
An example of such an effort is published in this issue of Oncology . Kemeny et al. [5] report a phase 2 trial of the hepatic arterial infusion of floxuridine and dexamethasone, plus the systemic delivery of bevacizumab, in the management of hepatocellular carcinoma. The investigators compare the outcome in this trial to their previously reported experience with this regional treatment strategy in this population in the absence of the administration of systemic bevacizumab [6] .
Prior to analyzing differences in measurable outcomes (response rates, time to disease progression, overall survival), the investigators directly evaluated (employing a variety of parameters known to be biologically and clinically relevant in influencing that outcome) the relative comparability of the two study populations [5] . Specifically, the researchers demonstrated no major differences in the groups as regards a number of factors (e.g. age; sex; specific cancer type; median tumor diameter, relevant baseline laboratory tests, and performance status; presence of symptomatic disease and portal vein thrombosis; multifocal vs. solitary disease).
While noting similar measures of efficacy (response rate, survival) between the two studies, the investigators then focused on the observed toxicity of the novel (bevacizumab-containing) regimen, specifically the risk of serious (grade 3-4) hepatic dysfunction [5] . Recognizing the limitations of comparing the clinical effectiveness of the two treatment approaches in this non-randomized setting, the investigators rationally stated that the observed serious side effect profile permitted the conclusion that this specific strategy should not be further pursued in the research setting and most certainly not in routine clinical practice.
The investigators are to be commended for their efforts to focus on toxicity, rather than efficacy, in this non-randomized (and less-than-definitive) clinical setting. While the reported data clearly do not, with statistical certainty, rule out the potential for superior efficacy to be associated with the delivery of the novel targeted therapy (in concert with the hepatic arterial infusion regimen), the analysis is surely both appropriate and sufficient for the intended and highly clinically relevant purpose of ensuring and optimizing patient safety.
